Advances and challenges in the treatment of lung cancer

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 169, P. 115891 - 115891

Published: Nov. 16, 2023

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most prevalent type lung cancer, non-small cell (NSCLC) is characterized by morbidity and mortality. Presently, arsenal treatment strategies encompasses surgical resection, chemotherapy, targeted therapy radiotherapy. However, despite these options, prognosis remains distressingly poor with low 5-year survival rate. Therefore, it urgent to pursue paradigm shift in methodologies. In recent years, advent sophisticated biotechnologies interdisciplinary integration has provided innovative approaches cancer. This article reviews cutting-edge developments nano drug delivery system, molecular photothermal strategy, immunotherapy Overall, systematically summarizing critically analyzing latest progress current challenges we aim provide theoretical basis development novel drugs treatment, thus improve therapeutic outcomes patients.

Language: Английский

---

Chimeric antigen receptor engineered natural killer cells for cancer therapy

Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)

Published: Aug. 10, 2023

Abstract Natural killer (NK) cells, a unique component of the innate immune system, are inherent killers stressed and transformed cells. Based on their potent capacity to kill cancer cells good tolerance healthy NK have been successfully employed in adoptive cell therapy treat patients. In recent years, clinical success chimeric antigen receptor (CAR)-T has proven vast potential gene-manipulated as main force fight cancer. Following lessons learned from mature gene-transfer technologies advanced strategies CAR-T therapy, rapidly explored promising candidate for CAR-based therapy. An exponentially growing number studies multiple sources CAR-NK target wide range cancer-related antigens, showing remarkable outcomes encouraging safety profiles. Clinical trials also shown impressive therapeutic efficacy treatment hematological tumors, but solid tumors is still initial stages. this review, we present favorable profile platform engineering then summarize therapies up-to-date preclinical investigations. Finally, evaluate challenges remaining describe existing that can assist us devising future prospective solutions.

Language: Английский

---

Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer

Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216780 - 216780

Published: March 8, 2024

Language: Английский

---

Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 853 - 853

Published: March 1, 2025

Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths globally. The study focuses on understanding the interplay between genetic mutations, stem cells (CSCs), and tumor microenvironment (TME) in driving NSCLC progression, resistance to therapies, relapse. A systematic search was conducted PubMed Scopus databases identify significant valuable studies relevant NSCLC, focusing CSCs, TME. Articles were selected based their relevance, methodological severity, date publication, scientific soundness related biology therapeutic strategies. This review synthesized findings from these sources highlight key mechanisms potential interventions. Mutations critical genes KRAS, EGFR, TP53, other interfere with regulation, promoting CSC-like behavior, therapy, immune evasion. (TME), including cells, fibroblasts, extracellular matrix components, further supports growth reduction treatment efficacy. Promising strategies, CSC targeting, TME modulation, development novel biomarkers, have shown preclinical clinical studies. association alterations, TME, cellular pathways-including metabolism evasion-plays crucial role therapy resistance, highlighting need for comprehensive combination genomic profiling TME-targeting therapies could lead personalized approaches, offering hope better outcomes reduced mortality patients.

Language: Английский

---

Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics

Biomaterials Research, Journal Year: 2023, Volume and Issue: 27(1)

Published: Feb. 9, 2023

Immune cell-based therapies are a rapidly emerging class of new medicines that directly treat and prevent targeted cancer. However multiple biological barriers impede the activity live immune cells, therefore necessitate use surface-modified cells for cancer prevention. Synthetic and/or natural biomaterials represent leading approach cell surface modulation. Different types can be applied to membranes through hydrophobic insertion, layer-by-layer attachment, covalent conjugations acquire modification in mammalian cells. These generate reciprocity enable cell–cell interactions. In this review, we highlight different (lipidic polymeric)-based advanced applications cell–surface modulation, few recognition moieties, how their interplay interaction. We discuss cancer-killing efficacy NK followed by engineering treatment. Ultimately, review connects biologically active play key roles immunotherapy applications.

Language: Английский

---

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Chinese Medical Journal, Journal Year: 2023, Volume and Issue: 137(11), P. 1285 - 1302

Published: Aug. 28, 2023

The advent of chimeric antigen receptor (CAR)-T cell immunotherapies has led to breakthroughs in the treatment hematological malignancies. However, their success treating solid tumors been limited. CAR-natural killer (NK) cells have several advantages over CAR-T because NK can be made from pre-existing lines or allogeneic with a mismatched major histocompatibility complex (MHC), which means they are more likely become an "off-the-shelf" product. Moreover, kill cancer via CAR-dependent/independent pathways and limited toxicity. Macrophages most malleable immune body. These efficiently infiltrate into present large numbers tumor microenvironments (TMEs). Importantly, CAR-macrophages (CAR-Ms) recently yielded exciting preclinical results tumors. Nevertheless, CAR-T, CAR-NK, CAR-M all own limitations. In this review, we systematically discuss current status, progress, hurdles cells, CAR-NK as relate five aspects: CAR structure, therapeutic mechanisms, latest research challenges solutions, comparison according existing order provide reasonable option for future.

Language: Английский

---

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 136, P. 112273 - 112273

Published: May 28, 2024

Cholangiocarcinoma (CCA) presents a significant clinical challenge which is often identified in advanced stages, therby restricting the effectiveness of surgical interventions for most patients. The high incidence cancer recurrence and resistance to chemotherapy further contribute bleak prognosis low survival rates. To address this pressing need effective therapeutic strategies, our study focuses on development an innovative cellular immunotherapy, specifically utilizing chimeric antigen receptor (CAR)-engineered natural killer (NK) cells designed target cMET tyrosine kinase. In investigation, we initiated screening phage library displaying human single-chain variable fragment (ScFv) identify novel ScFv molecules with specificity cMET. Remarkably, ScFv11, ScFv72, ScFv114 demonstrated exceptional binding affinity, confirmed by molecular docking analysis. These selected ScFvs, addition well-established anti-cMET ScFvA, were integrated into CAR cassette harboring CD28 transmembrane region-41BB-CD3ζ domains. resulting constructs transduced NK-92 cells, generating potent CAR-NK-92 cells. assess efficacy these engineered employed KKU213A expression KKU055 levels. Notably, co-culture resulted significantly increased cell death, whereas no such effect was observed summary, as promising CCA. armed molecule, have shown strong ability kill specifically, indicating their potential treatment CCA future.

Language: Английский

---

Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 17, 2024

Recent advancements in genetic engineering have made it possible to modify Natural Killer (NK) cells enhance their ability fight against various cancers, including solid tumors. This comprehensive overview discusses the current status of genetically engineered chimeric antigen receptor NK-cell therapies and potential for treating We explore inherent characteristics NK role immune regulation tumor surveillance. Moreover, we examine strategies used engineer terms efficacy, safety profile, clinical applications. Our investigation suggests CAR-NK can effectively target regress non-hematological malignancies, demonstrating enhanced antitumor efficacy. implies excellent promise tumors using modified cells. Notably, exhibit low graft versus host disease (GvHD) rarely induce significant toxicities, making them an ideal platform CAR engineering. The adoptive transfer allogeneic into patients further emphasizes versatility also address challenges limitations associated with translation therapies, such as off-target effects, escape mechanisms, manufacturing scalability. provide overcome these obstacles through combination delivery optimization. Overall, believe this review contributes advancing NK-cell-based immunotherapy a promising approach cancer treatment by elucidating underlying evaluating preclinical evidence, addressing remaining challenges.

Language: Английский

---

Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 9101 - 9101

Published: Aug. 22, 2024

Non-small cell lung cancer (NSCLC) is characterized by several molecular alterations that contribute to its development and progression. These include the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), human 2 (HER2), mesenchymal-epithelial transition (c-MET). Among these, hepatocyte (HGF)/c-MET signaling pathway plays a crucial role in NSCLC. In spite of this, involvement HGF/c-MET axis remodeling tumor microenvironment (TME) remains relatively unexplored. This review explores biological functions both normal cancerous cells, examining multifaceted roles NSCLC microenvironment, including proliferation, migration invasion, angiogenesis, immune evasion. Furthermore, we summarize current progress clinical applications MET-targeted therapies discuss future research directions, such as novel MET inhibitors potential combination immunotherapy.

Language: Английский

---

Harnessing Natural Killer Cells for Lung Cancer Therapy

Cancer Research, Journal Year: 2023, Volume and Issue: 83(20), P. 3327 - 3339

Published: Aug. 2, 2023

Abstract Lung cancer is the leading cause of cancer-related death worldwide. Although natural killer (NK) cells are garnering interest as a potential anticancer therapy because they selectively recognize and eliminate cells, their use in treating solid tumors, including lung cancer, has been limited due to impediments efficacy, such ability reach tumor tissues, reduced antitumor activity tumor-infiltrating NK suppressive microenvironment (TME). This comprehensive review provides an in-depth analysis cross-talk between TME cells. We highlight various mechanisms used by modulate NK-cell phenotypes limit infiltration, explore role limiting discuss current challenges obstacles that hinder success NK-cell–based immunotherapy for cancer. Potential opportunities promising strategies address these have implemented or being developed optimize Through critical evaluation existing literature emerging trends, this outlook on future

Language: Английский

---